PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Grifols announces phase 3 progress for Albutein

Therapy has the potential to decrease mortality rates in patients with decompensated cirrhosis.

Grifols – a company concentrating on plasma-derived treatments – has announced that enrolment has been finalised for its pivotal PRECIOSA clinical trial.

The phase 3 study has been developed in order to establish the potential of long-term albumin treatment using Grifols’ Albutein. The therapy is designed to increase survival time among patients with decompensated cirrhosis and ascites, until such time as a suitable transplant becomes available.

More than 400 patients with the two serious conditions are taking part in the multi-location, randomised open-label study across 69 sites across North America and Europe. The research will evaluate the safety and efficacy of long-term Albutein administration, alongside standard medical treatment.

Albumin – the most abundant protein in plasma – contains antioxidant and anti-inflammatory properties with the potential to alleviate complications linked with decompensated cirrhosis and its progression into acute-on-chronic liver failure (ACLF).

Incorporating albumin therapy has the potential to decrease the high one-year mortality rates typically observed in decompensated cirrhosis.

Sandra Camprubi, senior director, of clinical operations at Grifols, was optimistic about the phase 3 trial: “There is great potential for albumin to improve the survival prospects of patients suffering from decompensated cirrhosis until they can get a liver transplant, a large unmet need given the limited availability of livers for patients.”

She added: “We look forward to providing topline data from this study in the fourth quarter of 2024 and evaluating the next regulatory steps to provide patients with a much-needed treatment.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026